PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri Sells 5,306 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Free Report) EVP Alaleh Nouri sold 5,306 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $49.95, for a total transaction of $265,034.70. Following the completion of the transaction, the executive vice president now directly owns 47,351 shares of the company’s stock, valued at approximately $2,365,182.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Alaleh Nouri also recently made the following trade(s):

  • On Friday, February 9th, Alaleh Nouri sold 14,694 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $49.97, for a total transaction of $734,259.18.
  • On Tuesday, January 9th, Alaleh Nouri sold 16,000 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $44.97, for a total transaction of $719,520.00.
  • On Thursday, December 14th, Alaleh Nouri sold 3,204 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $42.95, for a total transaction of $137,611.80.
  • On Wednesday, December 6th, Alaleh Nouri sold 6,096 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $39.96, for a total transaction of $243,596.16.

PROCEPT BioRobotics Trading Up 0.9 %

Shares of PROCEPT BioRobotics stock opened at $49.94 on Friday. The company’s fifty day simple moving average is $44.07 and its two-hundred day simple moving average is $36.33. PROCEPT BioRobotics Co. has a 12-month low of $24.83 and a 12-month high of $50.48. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.91 and a quick ratio of 7.89.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently modified their holdings of PRCT. JPMorgan Chase & Co. lifted its position in shares of PROCEPT BioRobotics by 18.2% in the 1st quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company’s stock worth $188,000 after purchasing an additional 825 shares during the period. Bank of New York Mellon Corp lifted its position in PROCEPT BioRobotics by 59.8% during the 1st quarter. Bank of New York Mellon Corp now owns 22,079 shares of the company’s stock valued at $772,000 after acquiring an additional 8,265 shares during the period. MetLife Investment Management LLC purchased a new position in PROCEPT BioRobotics during the 1st quarter valued at about $175,000. Rhumbline Advisers purchased a new position in PROCEPT BioRobotics during the 1st quarter valued at about $253,000. Finally, BlackRock Inc. lifted its position in PROCEPT BioRobotics by 9.8% during the 1st quarter. BlackRock Inc. now owns 352,791 shares of the company’s stock valued at $12,344,000 after acquiring an additional 31,486 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PRCT. SVB Leerink began coverage on shares of PROCEPT BioRobotics in a research note on Monday, October 16th. They issued an “outperform” rating and a $37.00 price objective for the company. Wells Fargo & Company raised their price target on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a report on Tuesday, January 9th. Truist Financial raised their price target on shares of PROCEPT BioRobotics from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. Finally, Leerink Partnrs reissued an “outperform” rating on shares of PROCEPT BioRobotics in a report on Monday, October 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.00.

View Our Latest Analysis on PROCEPT BioRobotics

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Read More

Insider Buying and Selling by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.